Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Analyst. 2013 Jan 21;138(2):410-6. doi: 10.1039/c2an36128k.
Proteomic analyses of readily obtained human fluids (e.g., serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanoparticle-based multiplexed platform that has the potential for simultaneous read-out of large numbers of biomolecules. For this purpose, we have chosen pancreatic adenocarcinoma (PA) as a test bed for diagnosis and prognosis. PA is a devastating form of cancer in which an estimated 86% of diagnoses resulted in death in the United States in 2010. The high mortality rate is due, in part, to the asymptomatic development of the disease and the dearth of sensitive diagnostics available for early detection. One promising route lies in the development of a serum biomarker panel that can generate a signature unique to early stage PA. We describe the design and development of a proof-of-concept PA biomarker immunoassay array coupled with surface-enhanced Raman scattering (SERS) as a sensitive readout method.
从易于获得的人体体液（如血清、尿液和唾液）中进行蛋白质组学分析表明，通过同时测量这些样本中的多个生物标志物，将提高复杂疾病的诊断能力。本文描述了一种基于纳米颗粒的多重平台的开发，该平台具有同时读取大量生物分子的潜力。为此，我们选择胰腺导管腺癌 (PA) 作为诊断和预后的测试平台。PA 是一种毁灭性的癌症，据估计，2010 年在美国，86%的诊断结果导致死亡。高死亡率部分归因于疾病的无症状发展和缺乏用于早期检测的敏感诊断方法。一个有前途的途径在于开发一种血清生物标志物面板，可以生成早期 PA 特有的特征。我们描述了一种概念验证的 PA 生物标志物免疫分析阵列的设计和开发，该阵列与表面增强拉曼散射 (SERS) 相结合，作为一种敏感的读出方法。
